Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK1 | P51617 | 1/20 | 0.53 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 3/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19645707 | 0.82 | PDGFRB (0.53) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL31554474 | 0.81 | PDGFRB (0.52) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL31554584 | 0.81 | PDPK1 (0.54) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL2063193 | 0.81 | PDGFRB (0.52) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL12335689 | 0.80 | PDGFRB (0.50) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL15263519 | 0.79 | SRC (0.61) | EGFRSRCKDRPDGFRBPDGFRA | |
| SCHEMBL1893875 | 0.79 | SRC (0.61) | EGFRSRCKDRPDGFRBPDGFRA | |
| SCHEMBL5929650 | 0.79 | EGFR (0.53) | EGFRPDGFRBPDGFRAPDPK1KDM1A | |
| SCHEMBL5452461 | 0.79 | EGFR (0.49) | IRAK1IRAK4EGFRSRCKDR | |
| SCHEMBL168494 | 0.77 | PIN1 (0.49) | PDGFRBPDGFRAPDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| US-8148531-B2 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2012-04-03 | — | — | US | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| EP-1877383-B1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2011-09-07 | — | — | EP | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CHROMA THERAPEUTICS LTD. (GB) | 2009-05-21 | — | — | US | disclosed |
| EP-1877383-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| WO-2006117552-A1 | QUINOLINE AND QUINOXALINE DERIVATIVES AS INHIBITORS OF KINASE ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131461-A1 | Quinoline and quinoxaline derivatives as inhibitors of kinase enzymatic activity | CDK1, AURKC, CSNK1G3 | IRAK1 1891/4885IRAK4 2798/4885EGFR 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.